236 related articles for article (PubMed ID: 24337575)
1. Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.
Singha B; Gatla HR; Manna S; Chang TP; Sanacora S; Poltoratsky V; Vancura A; Vancurova I
J Biol Chem; 2014 Jan; 289(5):2687-700. PubMed ID: 24337575
[TBL] [Abstract][Full Text] [Related]
2. IKK inhibition increases bortezomib effectiveness in ovarian cancer.
Singha B; Gatla HR; Phyo S; Patel A; Chen ZS; Vancurova I
Oncotarget; 2015 Sep; 6(28):26347-58. PubMed ID: 26267322
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα.
Manna S; Singha B; Phyo SA; Gatla HR; Chang TP; Sanacora S; Ramaswami S; Vancurova I
J Immunol; 2013 Sep; 191(5):2837-46. PubMed ID: 23894194
[TBL] [Abstract][Full Text] [Related]
4. Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy.
Uddin MM; Zou Y; Sharma T; Gatla HR; Vancurova I
PLoS One; 2018; 13(8):e0201858. PubMed ID: 30089134
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
[TBL] [Abstract][Full Text] [Related]
6. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
7. IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Hideshima H; Yoshida Y; Ikeda H; Hide M; Iwasaki A; Anderson KC; Hideshima T
Int J Oncol; 2014 Apr; 44(4):1171-6. PubMed ID: 24481412
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
9. Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.
Lee KH; Jeong J; Yoo CG
J Biol Chem; 2013 Nov; 288(45):32777-32786. PubMed ID: 24085292
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun SY
J Biol Chem; 2010 May; 285(21):16096-104. PubMed ID: 20335171
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
12. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
14. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
15. Specific NFkappaB subunit activation and kinetics of cytokine induction in adenoviral keratitis.
Rajaiya J; Sadeghi N; Chodosh J
Mol Vis; 2009 Dec; 15():2879-89. PubMed ID: 20038977
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells.
Singha B; Phyo SA; Gatla HR; Vancurova I
Methods Mol Biol; 2014; 1172():295-304. PubMed ID: 24908316
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
Juvekar A; Manna S; Ramaswami S; Chang TP; Vu HY; Ghosh CC; Celiker MY; Vancurova I
Mol Cancer Res; 2011 Feb; 9(2):183-94. PubMed ID: 21224428
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells.
Zou P; Kawada J; Pesnicak L; Cohen JI
J Virol; 2007 Sep; 81(18):10029-36. PubMed ID: 17626072
[TBL] [Abstract][Full Text] [Related]
20. Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NFκB recruitment to IL-1β and TNFα gene promoters in human macrophages.
Sanacora S; Chang TP; Vancurova I
Methods Mol Biol; 2014; 1172():315-27. PubMed ID: 24908318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
